How Real-World Evidence is Reshaping GLP-1 Therapy

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are transforming diabetes and obesity management worldwide. Consequently, clinical interest in these therapies has grown rapidly in India and other countries. However, clinical trials do not always reflect routine healthcare settings. Therefore, medical experts are increasingly turning to real-world evidence to guide clinical and coverage decisions. This clinical summary explores key insights from a landmark National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop. Specifically, we examine how observational data can complement randomized trials for GLP-1 medications.

Why Real-World Evidence is Vital for GLP-1 Use

Randomized clinical trials provide excellent efficacy data under highly controlled conditions. Nevertheless, these trials often exclude diverse populations and fail to track long-term safety. In contrast, real-world evidence tracks everyday patients in routine clinical practice. Furthermore, observational data are vital to uncover rare adverse events, such as pancreatitis or thyroid disorders. This data is also critical because real-world patients often face challenges that trial participants do not experience. For instance, medication shortages and high costs frequently lead to early treatment discontinuation.

Indeed, real-world evidence helps clinicians understand medication persistence outside clinical trials. Specifically, recent analyses indicate that over half of patients stop taking GLP-1 medications within the first year. Consequently, real-world weight loss is often lower than trial outcomes. Ultimately, understanding these adherence barriers will help doctors optimize patient care and improve long-term metabolic health.

Unique Real-World Challenges and Data Gaps

In routine practice, several unique obstacles complicate the interpretation of observational data. For example, inconsistent insurance coverage and high out-of-pocket costs trigger frequent medication switching. Additionally, global drug shortages have forced many patients to use compounded formulations or turn to off-label prescribing. Consequently, electronic health records often lack complete information regarding actual drug exposure. Moreover, current datasets often exclude pediatric and underserved populations. Therefore, researchers must employ sophisticated analytical methods to reduce bias and control for confounding factors in observational studies.

Implications for Indian Clinicians and Healthcare Systems

The findings from the NIDDK workshop are particularly relevant to the clinical landscape in India. Specifically, Indian clinicians manage a massive burden of type 2 diabetes and obesity under a predominantly self-pay model. Because of this financial structure, medication adherence and cost-benefit ratios are critical clinical considerations. Furthermore, the introduction of newer agents like tirzepatide highlights the urgent need for local observational data. Recently, Indian real-world studies have begun to confirm the impressive metabolic benefits of these therapies in local patients. However, managing side effects and ensuring long-term persistence remain significant clinical challenges in daily practice.

Ultimately, robust observational research will support value-based treatment protocols. Additionally, continuous digital health platforms can help clinicians track real-time patient outcomes and dosage changes. Consequently, Indian healthcare systems must invest in better data infrastructure to optimize clinical, regulatory, and financial decisions.

Frequently Asked Questions

Q1: Why does real-world weight loss from GLP-1RAs often differ from clinical trial results?

In clinical trials, patients receive intense support and free medications, which ensures high adherence. However, routine clinical challenges like high costs and side effects often lead to early discontinuation. Consequently, real-world patients often achieve less weight loss because they cannot sustain the therapy.

Q2: How can real-world evidence improve the clinical use of GLP-1 therapies in India?

Real-world evidence provides crucial insights into how diverse populations respond to these medications over time. By tracking everyday patient outcomes, clinicians can better identify risk factors for early discontinuation and customize dosing schedules. Ultimately, this evidence helps design more cost-effective treatment pathways for self-paying patients.

References

1. Arterburn D et al. Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-25-05468. PMID: 42372278.
2. Gasoyan H et al. Real-world use of GLP-1 receptor agonists for weight management: a retrospective cohort study. Obesity. 2025;33(5):980-989.
3. Kumar A et al. Real-World Evidence of Tirzepatide in Indian Adults With Type 2 Diabetes: Significant Early Glycemic and Cardiometabolic Benefits. Indian J Endocr Metab. 2026;30(1):45-52.